-
Insights into the Global Cancer Immunotherapy Market to 2026 - Clinical Trials Insight by Phase, Company, Patient Segment and Drug Class - ResearchAndMarkets.com
26 Feb 2020 20:36 GMT
… profiles of the pharmaceutical companies that are … Trials: > 2300 Drugs In Trials
Commercially Available Cancer Immunotherapies: > 120
Cancer Vaccines … during cancer immunotherapy treatment resulting in higher … -2b)
20.4 Sylatron (Peginterferon Alpha-2b) …
-
GLOBAL MELANOMA DRUGS MARKET 2018-2028
11 Jun 2018 18:26 GMT
… )
- Ipilimumab (Yervoy)
- PegIntron (Sylatron)
- Proleukin (Aldesleukin)
- Pembrolizumab … Immunotherapeutic agents for melanoma
- Vaccines for melanoma
- Genetic therapies … for melanoma treatment
What issues will affect the melanoma drugs market?
Our …
-
Global Malignant Melanoma Drug Market Report 2018: Dosage, Price & Clinical Pipeline Outlook 2024
20 Apr 2018 07:17 GMT
… methods such as vaccine and immunotherapy. The recent FDA approvals of six … 5 Peginterferon alpha 2-b (Sylatron)
5.4.6 Interleukin- … 5 Inhibitors in Malignant Melanoma Treatment
5.5.1 Vemurafenib ( … 5 Chiron
14.6 Enzon Pharmaceuticals
14.7 GlaxoSmithKline
14.8 …
-
CytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update
06 Nov 2025 21:10 GMT
… Sylatron (peginterferon alfa-2b) prescribing information. U.S. Food and Drug … across multiple treatment modalities including antibody-drug conjugates ( … successfully complete clinical trials, including the ongoing … CytomX’s clinical trial product candidates are …
-
CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update
12 May 2025 10:15 GMT
… by increased clinical trial activities related to … expenses. ____________________________
1 SYLATRON Prescribing Information About … across multiple treatment modalities including antibody-drug conjugates ( … successfully complete clinical trials, including the …
About
© 1995-2025